Pharmaceutical maker Medicines Co. said Tuesday second-quarter earnings surged as demand for its angioplasty drug rose. The company also boosted its full-year guidance. Medicines said net income rose to $10.9 million, or 22 cents per share, from $1.3 million, or 2 cents per share, in the year-ago period. Wall Street expected earnings of 12 cents per share, according to Thomson Financial.

Revenue rose 40 percent to $59.4 million from $42.6 million last year, easily beating Wall Street's estimate of $52.9 million in revenue.

The revenue improvement was driven by sales of Angiomax. Angiomax is used in angioplasty surgery, which frees blood flow in arteries around the heart.

Medicines lifted its 2006 earnings guidance to the range of $6 million to $10 million, from a previous outlook of $4 million to $8 million. The company predicts 2006 sales between $205 million and $212 million, up from prior guidance of $200 million to $210 million.

NEWS ARCHIVES

2008

• September
• August
• July
• June
• May
• April
• March

2007

• April
• March
• February
• January

2006

• December
• November
• October
• September
• August
• July
• June
• May
• April
• March
• February
• January

2005

• December
• November
• October
• August
• June
• April
• March
• February

2004

• December

NEWSLETTER SIGNUP